Intermediatemolecular biology

CRISPR: Bacterial Adaptive Immunity

Overview

CRISPR-Cas is bacteria's adaptive immune system: it records viral DNA as spacers, transcribes them into guide RNAs, and Cas nucleases destroy matching invaders. This lesson covers the three stages and the diversity of Cas systems — the natural history behind the gene-editing revolution.

Learning objectives

  • Describe the three stages of CRISPR immunity
  • Explain spacer acquisition
  • Distinguish CRISPR types
  • Relate to genome editing

Adaptive immunity in bacteria

Unlike restriction enzymes (innate), CRISPR remembers: fragments of invading phage DNA are stored as 'spacers' between repeats — a heritable record of past infections.

Key idea

CRISPR = genetic memory of viruses. Adaptation → expression → interference.

Stage 1: Adaptation

Cas1–Cas2 complexes capture phage DNA fragments and integrate them as new spacers at the leader end of the CRISPR array — newest memories first, in chronological order.

Exam tip

Cas1/Cas2 = spacer acquisition. Leader-proximal spacers are the most recent infections.

Stage 2: Expression

The array is transcribed into pre-crRNA, processed into individual crRNAs (each with one spacer guide). In Type II systems, tracrRNA assists processing and Cas9 loading.

Watch out

crRNA provides specificity; Cas protein provides the cutting — guide + effector.

Stage 3: Interference

crRNA guides Cas effectors to complementary invader DNA; Cas9 cuts both strands (requiring a PAM sequence). PAM prevents self-targeting of the CRISPR array itself.

Takeaway

PAM = self vs. non-self discrimination. No PAM in the array, no autoimmunity.

Diversity and applications

Types I, II (Cas9), V (Cas12), VI (Cas13 — targets RNA): a vast natural toolkit. Repurposed for genome editing (see crispr article), diagnostics (SHERLOCK/DETECTR), and phage therapy.

Note

Cas13 targets RNA — used in diagnostics; Cas9/Cas12 target DNA.

Key points

  • Three stages: adaptation, expression, interference
  • Spacers record past infections
  • Cas1/Cas2 acquire spacers
  • PAM prevents autoimmunity
  • Type II = Cas9 system

Common misconceptions

✗ Myth: CRISPR was invented for gene editing.

✓ Truth: It's a natural bacterial immune system, discovered in 1987 and repurposed for editing in 2012.

✗ Myth: All CRISPR systems use Cas9.

✓ Truth: Cas9 is just Type II; Types I, V, VI use different effectors (Cas3, Cas12, Cas13).

Practice questions

Q1. New spacers are added at the:
  1. Leader end of the CRISPR array
  2. Trailer end
  3. Middle
  4. Random positions
Answer: A.

Chronological order: newest spacers sit leader-proximal.

Q2. In Type II CRISPR, the effector nuclease is:
  1. Cas9
  2. Cas1
  3. Cas3
  4. Cas13
Answer: A.

Cas9 guided by crRNA:tracrRNA performs the double-strand cut.

Q3. CRISPR adaptation requires:
  1. Cas1–Cas2
  2. Cas9 only
  3. Ribosomes
  4. ATP synthase
Answer: A.

The Cas1–Cas2 integrase complex captures and inserts new spacers.

Click a question to reveal the answer and explanation.

Frequently asked questions

Describe the three stages of CRISPR immunity.

Adaptation: Cas1–Cas2 integrate phage fragments as spacers. Expression: the array is transcribed and processed into crRNAs. Interference: crRNA-guided Cas nucleases cleave matching invader nucleic acids.

What is the role of PAM?

The protospacer-adjacent motif is required for Cas9 target recognition but absent from the CRISPR array — distinguishing invader DNA (cut) from self spacers (spared).

How does CRISPR differ from restriction-modification?

Restriction is innate (fixed specificities); CRISPR is adaptive — it acquires new spacers from encountered phages, providing heritable, updatable immunity.